Cleveland, OH and Durham, NC (PRWEB) May 23, 2013
NDI Medical, LLC, a venture and commercialization firm that funds and develops innovative neurodevice technologies, has launched its next portfolio company, Deep Brain Innovations, LLC (DBI). DBI will commercialize its groundbreaking technology that is designed to optimize deep brain stimulation (DBS) therapy for patients with Parkinson’s disease. Currently available DBS therapy is effective in treating Parkinson’s disease and generates more than $275 million in annual sales. However, NDI has validated an opportunity to further expand this market with a revolutionary approach to DBS.
DBI's proprietary Temporally Optimized Patterned Stimulation (TOPS™) technology is based on the seminal research of Dr. Warren Grill, the Addy Professor of Biomedical Engineering at Duke University. "After more than a decade of research we've discovered a way to ‘speak’ to the area of the brain that controls movement in persons with Parkinson’s disease. The stimulation patterns, somewhat akin to Morse code for the brain, were designed to be much more efficient than conventional DBS” said Grill. “This is vital because the gains we make in improved efficiency increase the longevity of implanted brain stimulation devices, thus reducing health care costs, risks, and complications associated with frequent battery replacement for persons with DBS Systems."
Dr. Grill, Chief Scientific Officer, and Geoff Thrope, President and veteran neurodevice entrepreneur, founded DBI on the basis of NDI’s model, which is to invest in and develop technologies in large markets where there is at least one validated product, but where critical needs still exist. Thrope and Grill previously sold their proprietary MEDSTIM system for the treatment of urinary incontinence to Medtronic, Inc. for $42 million, which followed this same successful
Copyright©2012 Vocus, Inc.
All rights reserved